Listed
2025-09
First close
INR 1.8032
split-adjusted
Since listing
+104156%
23 points—
Current
INR 1880.00
≈ $48.1 B · 2026-11-12 ET
Peak
INR 1904.50
≈ $48.8 B2026-11
Low
INR 1740.00
≈ $44.5 B2026-10
Latest change
-0.3%
2026-11-12 → 2026-11-13
Change since first
+6.8%
2026-10
52-week range
INR 1583.70 – INR 2046.90
Drawdown
-8.2%
Avg vol 3m
1.8M
Dividend yield
0.85%
Price history
Oct 12, 2026 – Nov 13, 2026
Monthly closes from Yahoo Finance, split-adjusted, dividends excluded. Earlier points are actual closes, not reconstructed.
DateCloseMarket capChange
- 11-13INR 1880.00$48.1 B-0.3%
- 11-12INR 1885.00$48.3 B-0.9%
- 11-11INR 1902.30$48.7 B-0.1%
- 11-09INR 1904.50$48.8 B+2.4%
- 11-06INR 1860.00$47.6 B+1.7%
- 11-05INR 1829.00$46.8 B+3.1%
- 11-04INR 1773.40$45.4 B+0.2%
- 11-03INR 1769.90$45.3 B0.0%
- 11-02INR 1770.00$45.3 B-0.4%
- 10-30INR 1777.70$45.5 B+0.9%
- 10-29INR 1761.00$45.1 B+0.2%
- 10-28INR 1757.50$45 B+0.4%
- 10-27INR 1751.20$44.8 B+0.6%
- 10-26INR 1740.00$44.5 B-0.5%
- 10-23INR 1748.00$44.8 B-0.6%
- 10-22INR 1758.00$45 B+0.7%
- 10-21INR 1745.10$44.7 B+0.1%
- 10-19INR 1743.00$44.6 B-0.9%
- 10-16INR 1758.80$45 B-0.3%
- 10-15INR 1764.00$45.2 B+1.0%
- 10-14INR 1746.40$44.7 B-1.4%
- 10-13INR 1770.70$45.3 B+0.6%
- 10-12INR 1760.00$45.1 B—
Ownership & Control
Shareholding as of 2026-11-11- Controlling entity
- Dilip Shanghvi & Promoter Group (including Shanghvi Finance Pvt. Ltd.) — 54.48%
- Insiders
- —
- Institutions
- —
- Free float
- —
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →- LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor2026-09-28
- Sun Pharma 1QFY27 Results: Consolidated Revenue and EBITDA Deliver In-Line Growth Led by Domestic Formulations and Global Specialty Portfolio2026-08-03
- Sun Pharmaceutical Industries Publishes Annual Report Highlighting Global Specialty Expansion and INR 584.62 Billion FY26 Revenue2026-05-22
